Skip to main content
letter
. 2021 Nov 8;12(3):1025–1028. doi: 10.1016/j.jceh.2021.10.149

Table 1.

Clinical Characteristics of the 6 Patients Who Presented with New Onset PVT.

Patient Details Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Age (Years) 38 45 53 55 56 48
Sex Male Male Male Female Female Male
Etiology of Liver Disease Ethanol Ethanol Ethanol HCV NAFLD NAFLD
Co morbidity None Hypertension None None Diabetes mellitus Diabetes mellitus
COVID19 Infection Yes Yes No Yes Yes No
Severity of COVID-infection Mild Moderate (Oxygen requiring) Moderate (Oxygen requiring) Mild
Vaccination No No Yes Yes No Yes
Number of doses received 1 1 2
Use of anticoagulation in the last 6 months No No No Yes. 5 days of LMW heparin. No No
Use of Steroids in the last 6 months No No No No Yes No
Time period between COVID19 to detection of PVT (Days) 70 90 NA 90 60 NA
Time period between COVID19 vaccination to detection of PVT (Days) NA NA 110 60 NA 90
Time period between date of last surveillance ultrasound Doppler examination till detection of new PVT (Days) 120 90 60 90 90 120
PVT Main Main Eccentric PVT Branch Main Main
SMVT No No Yes No No No
ST No No Yes No No No
Presentation Pain Variceal Bleeding Pain Increasing ascites Variceal Bleeding New onset ascites
Other Decompensation Ascites Hepatic Encephalopathy Ascites
CTP 9 9 9 12 13 12
MELDNa 11 13 14 15 18 18
COVID antibody titre (CLIA) 14.9 12.5 Not done 8.5 Not done 7.45
JAK2 mutation Negative Negative Negative Negative Negative Negative
Factor V Leiden mutation Negative Negative Negative Negative Negative Negative
Treatment On Variceal Eradication On Variceal Eradication On Dabigatran Expired due to secondary sepsis, bacterial pneumonia Expired due to systemic sepsis, difficult to treat SBP. On variceal eradication
Hill’s Criteria
Temporality ++ ++ ++ ++ ++ ++
Biological Plausibility + + ++ + + ++
Likelihood of causal relationship with Vaccine Probable association Possible association Probable association

Abbreviations: CTP, Child Turcotte Pugh score; CLIA, chemiluminescent immunoassay; JAK2, Janus kinase 2 gene mutation; PVT, portal vein thrombosis; LMWH, low molecular weight heparin; HCV, hepatitis C virus; NAFLD, nonalcoholic fatty liver disease; SBP, spontaneous bacterial peritonitis.